Product Overview
Dermorphin is a highly potent hepta-peptide originally isolated from the cutaneous secretions of South American frogs belonging to the genus Phyllomedusa. Distinctly recognised as a naturally occurring mu-opioid receptor (MOR) agonist, it has become a fundamental tool within advanced neuropharmacological assays. Laboratory research frequently employs this compound due to its exceptional affinity and selectivity, which vastly exceeds that of conventional morphinan derivatives in binding models.
This lyophilised compound is synthesised under rigorous quality control standards to ensure maximum fidelity for in vitro and animal model investigations. Researchers investigating nociception, cellular signal transduction, and receptor internalisation rely on its structural stability. Every batch is subjected to comprehensive high-performance liquid chromatography (HPLC) to guarantee a purity exceeding 99%, ensuring reproducible and precise laboratory data.
Technical Specifications
- Chemical Name: Dermorphin
- CAS Number: 77614-16-5
- Sequence: H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2
- Molecular Formula: C40H50N8O10
- Molecular Weight: 802.9 g/mol
- Target: Mu-opioid receptor (MOR)
- Mechanism: Selective mu-opioid receptor agonism
- Half-Life: ~1-2 hours (dependent on experimental model)
- Format: Lyophilised Solid
- Appearance: White crystalline powder
- Grade: Laboratory / Analytical Grade
- Purity: >99% HPLC Verified
Variant Breakdown
- 2mg lyophilised vial
- Closure: Rubber stopper with flip-off aluminium seal.
Research Mechanism (Mechanism of Action)
Dermorphin exerts its biochemical effects by binding with extraordinary affinity to the mu-opioid receptor, thereby initiating a complex G-protein coupled transduction cascade. A critical structural feature of this peptide is the presence of a D-alanine residue at the second position. This stereochemical anomaly protects the sequence from rapid enzymatic cleavage by aminopeptidases, conferring superior stability in vitro when compared to endogenous mammalian ligands such as enkephalins.
Upon receptor activation, the compound effectively inhibits the enzyme adenylate cyclase, resulting in a marked reduction of intracellular cyclic AMP (cAMP) concentrations. This downstream effect subsequently restricts voltage-gated calcium channels whilst facilitating the opening of inwardly rectifying potassium channels. These combined cellular events hyperpolarise the neuronal membrane, actively attenuating the exocytosis of excitatory neurotransmitters. Investigators utilise this mechanism to isolate specific opioid pathways and evaluate receptor desensitisation dynamics in controlled models.
Safety, Handling & Reconstitution
For optimal stability and solubility, researchers should reconstitute the lyophilised powder using Bacteriostatic Reconstitution Solution (0.9% Benzyl Alcohol). Dilution ratios should be calibrated according to the specific parameters of the experimental assay. Prior to reconstitution, the lyophilised compound must be stored at -20°C. Following successful dissolution, the reagent should be maintained safely at 2°C to 8°C to prevent degradation.
Strict Warning: This product is classified exclusively for Laboratory Research Purposes Only. It is strictly not intended for human consumption, diagnostic application, or animal therapeutic use.
Scientific References (External Links)
[International Journal of Peptide and Protein Research]: “Amino acid composition and sequence of dermorphin, a novel opiate-like peptide from the skin of Phyllomedusa sauvagei” View Study
[Peptides]: “Dermorphin, a new opiate peptide from amphibian skin” View Study
[Journal of Medicinal Chemistry]: “Synthesis and structure-activity relationships of dermorphin analogues” View Study
[European Journal of Pharmacology]: “Effects of dermorphin and its derivatives on the central nervous system” View Study
